204 related articles for article (PubMed ID: 34511006)
1. Combining the past and present to advance immuno-radiotherapy of cancer.
Koukourakis IM; Koukourakis MI
Int Rev Immunol; 2023; 42(1):26-42. PubMed ID: 34511006
[TBL] [Abstract][Full Text] [Related]
2. Lymphopenia and intratumoral lymphocytic balance in the era of cancer immuno-radiotherapy.
Koukourakis MI; Giatromanolaki A
Crit Rev Oncol Hematol; 2021 Mar; 159():103226. PubMed ID: 33482348
[TBL] [Abstract][Full Text] [Related]
3. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Wirsdörfer F; de Leve S; Jendrossek V
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
[TBL] [Abstract][Full Text] [Related]
4. The role of radiotherapy in the age of immunotherapy.
Sato H; Demaria S; Ohno T
Jpn J Clin Oncol; 2021 Apr; 51(4):513-522. PubMed ID: 33561212
[TBL] [Abstract][Full Text] [Related]
5. Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.
Marciscano AE; Walker JM; McGee HM; Kim MM; Kunos CA; Monjazeb AM; Shiao SL; Tran PT; Ahmed MM
J Immunother Cancer; 2018 Jan; 6(1):6. PubMed ID: 29375032
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Cytokines: Signalling Improved Immunotherapy?
De Luca AJ; Lyons AB; Flies AS
Curr Oncol Rep; 2021 Jul; 23(9):103. PubMed ID: 34269916
[TBL] [Abstract][Full Text] [Related]
8. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
Kleinendorst SC; Oosterwijk E; Bussink J; Westdorp H; Konijnenberg MW; Heskamp S
Clin Cancer Res; 2022 Sep; 28(17):3652-3657. PubMed ID: 35471557
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
10. Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors.
Baues C; Trommer-Nestler M; Jablonska K; Bröckelmann PJ; Schlaak M; von Bergwelt-Baildon M; Engert A; Semrau R; Marnitz S; Theurich S
Immunotherapy; 2017 Mar; 9(5):423-433. PubMed ID: 28357914
[TBL] [Abstract][Full Text] [Related]
11. Exploring low-dose radiotherapy to overcome radio-immunotherapy resistance.
Wang J; Zhang J; Wen W; Wang F; Wu M; Chen D; Yu J
Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166789. PubMed ID: 37302425
[TBL] [Abstract][Full Text] [Related]
12. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
13. [Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics].
; Ai X; Cai Y; Chu Q; Han C; Lu Y; Qin S; Wu L; Xie C; Yuan Z; Zhong W; Zhu X; Chang JY; Zhu Z
Zhongguo Fei Ai Za Zhi; 2020 Jun; 23(6):532-540. PubMed ID: 32517461
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy.
Dong Q; Xue T; Yan H; Liu F; Liu R; Zhang K; Chong Y; Du J; Zhang H
J Nanobiotechnology; 2023 Oct; 21(1):395. PubMed ID: 37899463
[TBL] [Abstract][Full Text] [Related]
15. [Immuno-radiotherapy: A review of the rationale, recent clinical developments and future prospects].
Serre R; Deutsch E; Huguet F; Pointreau Y
Cancer Radiother; 2022 Oct; 26(6-7):955-961. PubMed ID: 36030189
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
[TBL] [Abstract][Full Text] [Related]
17. Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives.
Mortezaee K; Najafi M
Crit Rev Oncol Hematol; 2021 Jan; 157():103180. PubMed ID: 33264717
[TBL] [Abstract][Full Text] [Related]
18. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H
Front Immunol; 2018; 9():1739. PubMed ID: 30100909
[TBL] [Abstract][Full Text] [Related]
19. Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect.
Theelen WS; de Jong MC; Baas P
Lung Cancer; 2020 Apr; 142():106-113. PubMed ID: 32126451
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
